Global

Alpha 1 Antitrypsin Deficiency & Pulmonary

FACT

Up to 100,000 people in US may have Alpha-1 deficiency.

90% of those are undiagnosed.

About 25 million people in the US may be carriers of the defective Alpha-1 gene.

If undetected 75-85% of patients with severe Alpha-1 Antitrypsin Deficiency will develop emphysema.

Alpha-1 is an inherited disorder.

Alpha-1 is more common than better known disorders such as cystic fibrosis but is frequently misdiagnosed or undiagnosed.

About Our Therapies
Product List
Resources

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.

Product availability varies from country to country, depending on registration status.
Please contact your CSL Behring representative for more information.

Treatment Area Product Name Generic Name Product Description
Emphysema due to alpha-1 antitrypsin deficiency Zemaira®
Respreeza®
Human alpha1-proteinase inhibitor Alpha1-proteinase inhibitor
(A1-PI)

 
Share
LinkedIn Twitter Facebook Google+